From: Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis
Patients With Only First-line Anti-TNFα Biologic Therapy (n = 881)a | Patients With Second-line Anti-TNFα Biologic Therapy (n = 72)a | Patients with Third-line or Greater of Anti-TNFα Biologic Therapy (n = 37)a | |
---|---|---|---|
Persistent use of anti-TNFα biologic therapy (days), mean (SD)b | |||
First-line | 522.3 (418.9) | 348.5 (308.7) | 325.2 (239.9) |
Second-line | N/A | 447.3 (327.6) | 126.8 (197.9) |
Third-line or greater | N/A | N/A | 251.6 (305.2) |
Time to switch anti-TNFα biologic therapy(days), mean (SD)c | |||
First-line | N/A | 349.5 (308.7) | 326.2 (239.9) |
Second-line | N/A | N/A | 127.8 (197.9) |
Third-line or greater | N/A | N/A | 40.2 (49.8) |
Time to first modification of anti-TNFα biologic therapy (days), mean (SD)d,e | |||
First-line | 119.4 (208.7) | 58.4 (102.7) | 219.8 (295.4) |
Second-line | N/A | 189.5 (226.0) | 76.1 (238.9) |
Third-line or greater | N/A | N/A | 24.3 (33.3) |
Time from first modification of anti-TNFα biologic therapy to switch (days), mean (SD)f | |||
First-line | N/A | 385.3 (277.1) | 143.5 (199.0) |
Second-line | N/A | N/A | 38.1 (53.7) |
Third-line or greater | N/A | N/A | 42.0 (65.6) |